The sound of tablets during coating erosion, disintegration, deaggregation and dissolution by O'Mahoney, Niamh et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title The sound of tablets during coating erosion, disintegration,
deaggregation and dissolution
Author(s) O'Mahoney, Niamh; Keating, John J.; McSweeney, Seán; Hill, Sam;
Lawrence, Simon E.; Fitzpatrick, Dara
Publication date 2020-03-09
Original citation O'Mahoney, N., Keating, J. J., McSweeney, S.,  Hill, S., Lawrence, S. E.
and Fitzpatrick, D. (2020) 'The sound of tablets during coating erosion,
disintegration, deaggregation and dissolution',  International Journal of
Pharmaceutics, 580, 119216 (10 pp). doi:
10.1016/j.ijpharm.2020.119216





Access to the full text of the published version may require a
subscription.
Rights © 2020 Elsevier B. V. All rights reserved. This manuscript version is
made available under the CC BY-NC-ND 4.0 license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Embargo information Access to this article is restricted until 12 months after publication by
request of the publisher.






The Sound of Tablets during Coating Erosion, Disintegration, 1 
 Deaggregation and Dissolution. 2 
Niamh O’Mahoney 
a
, John J. Keating 
a,b











a Department of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF), University College 6 
Cork, Ireland 7 
b School of Pharmacy, University College Cork, Ireland  8 
c BARDS Acoustic Science Labs, Bio-Innovation Centre, UCC, Ireland 9 
d GlaxoSmithKline R&D, Pharmaceutical Development & Supply, Ware, UK.  10 
Abstract 11 
This research aims to address a gap in our understanding of the mechanisms by which 12 
pharmaceutical tablets achieve highly reproducible and predictable drug release. The present 13 
industrial and regulatory practice is centred around tablet dissolution, i.e. what follows 14 
disintegration, yet the vast majority of problems that are found in formulation dissolution testing 15 
can be traced back to the erratic disintegration behaviour of the medicinal product. It is only due 16 
to the distinct lack of quantitative measurement techniques for disintegration analysis that this 17 
situation arises. Current methods involve costly, and time-consuming test equipment, resulting in 18 
a need for more simple, green and efficient methods which have the potential to enable rapid 19 
development and to accelerate routine solid drug formulation dissolution and disintegration 20 
testing. In this study, we present a novel approach to track several sequential tablet dissolution 21 
processes, including coating erosion, disintegration, deaggregation and dissolution using 22 
Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS). BARDS, in combination 23 
with minimal usage of UV spectroscopy, can effectively track these processes. The data also 24 
show that a solid oral dose formulation has an intrinsic acoustic signature which is specific to the 25 
method of manufacture and excipient composition.  26 
*Manuscript
Click here to view linked References
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1. Introduction 27 
 28 
Standard dissolution testing is a familiar, routine and regulatory test for product release for a 29 
wide range of formulations. Typical apparatus consists of ~6 stirred dissolution vessels which are 30 
sampled periodically either manually or automatically in order for drug concentration to be 31 
determined. The apparatus has been standardised and in use by the pharmaceutical industry for 32 
decades with little adaptation. The methodology of tablet disintegration and hardness testing are 33 
also rudimentary in design and operation. Traditional approaches to characterising tablets include 34 
visual observations of disintegration, tablet hardness testing and dissolution testing where the 35 
concentration of drug in solution is used to determine an endpoint via Ultra Violet-Visible 36 
Spectroscopy (UV-Vis) and/or High-Performance Liquid Chromatography (HPLC) 37 
measurements. There have been few if any disruptive technologies in this pharmaceutical 38 
physical testing space for many years, most likely due to regulatory protocols
1
 and this is likely 39 
to remain the status quo in the long term. However, given the time and expense of standard 40 
dissolution testing and associated delays with batch release, there is an onus on the industry to 41 
explore faster, greener and more data-rich complimentary dissolution methods to statistically and 42 
scientifically support current testing methods. 43 
Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) is one such approach which 44 
offers a complimentary and possible surrogate to standard dissolution testing based on the speed 45 
of real-time data acquisition and how the data can be extrapolated to match standard regulatory 46 
methods. BARDS is based on an acoustic phenomenon first described by A.B. Wood (1930) .
2
 It 47 
was most notably characterised by Frank S. Crawford in a series of papers published during the 48 
early 1980s, giving the phenomenon the title of the ‘hot chocolate effect’. 
2, 3
 Since its discovery, 49 
the effect has been intermittently discussed in the literature. 
4-9
 However, it was not until 2012 50 
that its significance as an investigative tool for the analysis of powders, tablets and compounds, 51 
in general, was realised with the development of BARDS. 
10, 11
 52 
The underlying principles of BARDS have been reported extensively in the literature summary,  53 
a BARDS signal results from reproducible changes in the compressibility of a solvent during the 54 
dissolution of a compound. The compressibility change alters the speed of sound, resulting in 55 
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frequency changes within the solution. The sound velocity (v) in a medium, whether in air or a 56 
liquid phase, is determined by eqn (1). 57 
          
 
  
   Equation 1 58 
where ρ =  mass density in kg/m
3
 and K = compressibility, the inverse of the bulk modulus, of 59 
the medium. Generation of micro gas bubbles in a liquid decreases the density in a negligible 60 
way in comparison to the significant increase in compressibility. The net effect is a substantial 61 
reduction of the sound velocity in the liquid. The relationship between the fractional bubble 62 





                     Equation 2 64 
where vw and v are the sound velocities in pure and bubble-filled water, respectively and fa is the 65 
fractional volume occupied by air bubbles. The factor, 1.49 x 10
4
, in eqn (2) was calculated, as 66 
shown in eqn (3): 67 
    
   
 
  
               Equation 3 68 
where ρw = the density of water, γ = the ratio of specific heats for dry air and ρ = the atmospheric 69 
air pressure. Eqn (2) is based on the approximation, which was initially presented by A. B. 70 
Wood
12
. BARDS analysis of an induced acoustic excitation of the containing vessel is focused 71 
on the lowest variable frequency-time course, i.e., the fundamental resonance mode of the liquid.  72 
The fundamental resonant frequency is determined by the sound velocity in the liquid and the 73 
approximate but fixed height of the liquid level, which corresponds to one-quarter of its 74 
wavelength. The frequency response is described as; 75 
     
     
              
   Equation 4 76 
where freqw and freq are the resonance frequencies of the fundamental resonance modes in pure 77 
and bubble-filled water, respectively. The transient total volume of the gas bubbles is determined 78 
by introduced entrained gas bubbles, bubbles evolving due to gas oversaturation, and bubbles 79 
disappearing due to elimination at the surface. A detailed and comprehensive outline of the 80 





The acoustic profile of interest is called the fundamental curve. The frequency minimum (fmin) 82 
represents an equilibrium between the rate of formation of gas in solution and the rate of gas 83 
liberation at the surface. In BARDS analysis, the fundamental curve is used to make comparisons 84 
between individual experiments. As an example, Figure 1 shows a typical BARDS spectrum of 85 
the dissolution of sodium carbonate in 25 mL of deionised water. Note the overtones and 86 
harmonics also changing above the fundamental curve.  87 
Figure 1  88 
In general, entrained gas, between and within particles, are introduced into the solution, when a 89 
compound/sample is wetting and/or dispersing in an aqueous solvent. Also, a reduction in the 90 
solubility of gases in solution will take place during dissolution, resulting in gas oversaturation. 91 
This oversaturation is partly removed by the generation of gas bubbles where nucleation sites are 92 
available. The entrainment and liberation of gas bubbles and their subsequent escape from the 93 
solution causes a transient yet reproducible change in the compressibility of the solution which 94 
can be monitored acoustically, under standardised conditions.
13
  95 
BARDS is also applied initially in this study to give an indication of tablet coating thickness and 96 
consistency. The use of BARDS as an in-process technique to track coating thickness in real-97 
time has been previously reported 
13-16
. Current methods of monitoring coating thickness include 98 
scanning electron microscopy (SEM)
17
 energy dispersive X-ray imaging (EDX), 
18
 fluorescence 99 
microscopy 
19
, confocal laser scanning microscopy (CLSM) 
20
, atomic force microscopy (AFM), 100 
confocal Raman micro-imaging 
21, 22
 air-coupled acoustics 
23
, direct/contact ultrasonic methods
24
 101 
and Optical Coherence Tomography (OCT). The ability of terahertz pulsed imaging to analyse 102 
coatings have also been reported with the capability to interrogate single drug-containing pellets, 103 
yielding quantitative measurements 
25
.  104 
Pantoprazole is among the top twenty selling drugs in the world under various trade names
26
. It 105 
is an over the counter and prescription medication used in the treatment of symptomatic gastro-106 
oesophageal reflux disease, prophylaxis and treatment of gastroduodenal ulcers. It is 107 
administered as a racemic mixture of R‐ (+)‐ pantoprazole and S‐ (–)‐ pantoprazole27 with 108 
weakly basic and acidic properties. Pantoprazole is one of several approved irreversible proton 109 
pump inhibitors (PPIs) which have been used worldwide over the past 25+ years. PPIs suppress 110 
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 ‐ ATPase on the cell 111 
membranes of gastric parietal cells
28
.  112 
Pantoprazole is commercially available as an oral suspension and as enteric-coated tablets
29
. The 113 
stability of the drug in aqueous solution is pH-dependent, where the rate of degradation increases 114 
with decreasing pH. Pantoprazole is preferably absorbed in the small intestine
30
. Therefore, an 115 
enteric coating is utilised in formulations of the drug to prevent drug degradation in the stomach 116 
before its systemic absorption.  117 
Functional enteric coatings control the location of drug release within the digestive system from 118 
solid oral dosage forms
31
. The most commonly used enteric coating polymer classes are the 119 
poly(meth)acrylates known in general as Eudragit®, manufactured by Evonik 
®
. These polymers 120 
are chemically designed to target drug release within the gut depending on the pH environment.  121 
Tablets coated with enteric coating polymeric excipients are typically designed to dissolve to 122 
allow subsequent drug release in the small intestine which has an enteral alkaline pH of about 7-123 
9. The majority of currently used enteric coating polymers are weak acids (pKa typically ~5) 124 
which remain un-dissociated in the low pH environment of the stomach, depending on their pKa, 125 
but readily ionise in pH environments above their pKa.
32
 The polymer may be applied at very 126 
thin coating thicknesses to tablet or pellet surfaces. 127 
The pharmaceutical industry uses enteric coating for a variety of reasons including protecting 128 
both the stomach from the drug and the drug from the stomach, allowing the safe release of the 129 
drug further along the intestinal tract, protecting acid-liable drugs from gastric fluid and to 130 
impart a delayed-release effect to the formulation. It also protects formulations against light and 131 
oxidation, thus improving product stability. In this study, most of the tablets under investigation 132 
are coated with the 1:1 methacrylic acid-ethyl acrylate anionic copolymer Eudragit® L30 D-55, 133 
available commercially as a 30% aqueous dispersion and used to impart enteric protection to the 134 
surfaces of solid oral dosage forms.  135 
Several coated pantoprazole-containing branded formulations were procured, which were 136 
produced by the same manufacturer (product license holder). These medicinal products were also 137 
chosen due to their inclusion of the polymer coating excipient Eudragit L30 D-55. BARDS is 138 
employed in experiments throughout this study to demonstrate how the copolymer loading and 139 
the processes of disintegration, deaggregation and dissolution can be tracked for tablets produced 140 
6 
 
by three different companies but sold under six different brand names. The concept of an 141 
Erosion, Disintegration, Deaggreation, Dissolution and coating Integrity (EDDDI) Plot to track 142 
all these processes is also introduced. BARDS, in combination with minimal usage of UV 143 
spectroscopy, can effectively track EDDDI processes of the tablets understudy while also 144 
providing a new measure of medicinal product integrity. The data also shows that a solid oral 145 
dose formulation has an intrinsic acoustic signature which is specific to the method of 146 
manufacture and excipient composition. BARDS represents a possible future surrogate / 147 
orthogonal quality control and presumptive test for tablet dissolution mapping and fingerprinting 148 
prior to product market release. BARDS data correlate directly with the integrity of formulation 149 
enteric coating and also with drug release as validated by UV-Vis spectroscopy. 150 
  151 
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2. Experimental 152 
2.1 Materials 153 
Sodium hydroxide of analar grade was purchased from Sigma Aldrich and Riedel-de Haën, Lot 154 
number STBG9017. Doubly distilled water was used for all experiments. Pantoprazole-155 
containing tablets were purchased from a local pharmacy as outlined in Table 1 156 
Table 1: 157 
2.2 Instrumentation 158 
 159 
A BARDS spectrometer acquired from BARDS Acoustic Science Labs (BASL) was used to 160 
analyse all samples. The spectrometer consists of a chamber containing a glass dissolution 161 
vessel, stir bar, a magnetic stirrer and microphone. There is access at the front for the dissolution 162 
vessel and at the top to allow a sample in a weighing boat to be placed on a tipper motor for the 163 
introduction of the solute. The resonances of the liquid vessel are recorded in a frequency band 164 
of 0-20 kHz. The glass vessel containing 25 mL of 0.06 M aq. sodium hydroxide (NaOH) is 165 
placed on the stirrer plate. The stirrer motor is located underneath this plate and allows the stir 166 
bar to tap the side of the vessel gently. The stirrer rate is set to 500 rpm. The follower acts as a 167 
source of broadband acoustic excitation, thereby inducing various acoustic resonances in the 168 
glass, the liquid and the air column above the liquid. The induced acoustic resonances are 169 
registered by the microphone and converted to a spectrum using a computer with a sound card 170 
and generic software, as seen in Figure 3. 171 
 172 
2.3 Experimental Procedure 173 
 174 
In a typical experiment, the spectrometer records the steady-state resonances of the system as a 175 
reference for 30 seconds (s) once the stirrer is set in motion. The pitch of the resonance modes in 176 
the solution change when each pantoprazole-containing tablet under investigation is added, 177 
before gradually returning to a steady-state over 3000 s (50 minutes). The frequency-time course 178 
of the fundamental resonance is presented, as manually extracted data from the total acoustic 179 
response. All experiments were performed in triplicate, and an average reading with error bars 180 
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representing the standard deviation is presented. The time courses of the observed acoustic 181 
profiles are shown to be reproducible under standardised conditions (constant volume, mass, 182 
temperature and stirring rate). The steady-state frequency before the addition of the solute is 183 
designated as the ‘volume  184 
Figure 2 185 
 186 
3. Results and Discussion 187 
Pantoprazole tablets are commercially available in two typical dosage forms, containing either, 188 
20 mg or 40 mg of active pharmaceutical ingredient (API) (equivalent to 22.6 mg and 45.2 mg 189 
pantoprazole sodium sesquihydrate respectively). EDDDI analysis of a variety of formulations 190 
from multiple manufacturers (Table 1) was performed and described below.  191 
The analysis of Pantoprazole Mylan (40 mg) tablets was initially undertaken in various 192 
concentrations of aq. NaOH in order to investigate the effect of media concentration and pH on 193 
the erosion of the coating and the initial lag time in BARDS spectra. The lag time is the duration 194 
(in seconds) of the frequency-time course after the addition of the tablet, which remains 195 
unchanged as the coating erodes. Once the enteric coating has eroded, the tablet core begins to 196 
disintegrate, and there is a significant decrease in frequency due to evolution of entrained gas in 197 
the tablet and gas oversaturation of the dissolution medium as API and excipients dissolve. All 198 
experiments were carried out in triplicate.  199 
Figure 3 200 
Figure 3 shows the acoustic frequencies of the glass vessel remaining at steady state for all 201 
profiles for the first 30 s of the spectra until the addition of the sample. After that, the resonance 202 
frequency of all profiles at 9.4 kHz decreases insignificantly to 9.38 kHz after tablet addition due 203 
to the extra volume of the tablet, which increases the liquid level and so decreases the final 204 
volume line resonance frequency. The lag phase for the green profile (0.06 M aq. NaOH) 205 
continues until the enteric coating is eroded after 500 s, indicating a complete loss of the coating 206 
from the tablet surface, after which point a frequency minimum (fmin) of 8.4 kHz is reached due 207 
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to core disintegration. The curve then gradually returns to a steady state after approximately 2000 208 
seconds.  209 
A decreasing concentration of aq. NaOH causes the lag time to increase, i.e. the enteric coating 210 
erodes more slowly. Coating erosion is a chemical process due to the interaction of the basic 211 
media and the carboxylic acid groups on the polymer. The greater the rate at which the polymer 212 
carboxylic acid groups become deprotonated under the influence of base, the more highly ionised 213 
(and hydrophilic) the polymer becomes, thereby facilitating its dissolution into the basic medium 214 
and loss from the tablet surface. No gas evolution occurs due to this process but gas 215 
oversaturation increases. This can be tracked by dissolved oxygen measurement using a DO 216 
probe.
23 
Once disintegration takes place, the overpressure at the electrode decreases due to the 217 
smaller particulates acting as nucleation points for gas to evolve. 218 
Somac Control® and Pantoloc Control® are both manufactured by Takeda but marketed by 219 
Takeda and GlaxoSmithKline (GSK), respectively. The solvent used for the EDDDI BARDS 220 
analysis of these tablet formulations was 0.01 M aq. The time it takes for the enteric coating to 221 
erode is directly related to the hydroxide ion concentration in solution
15
. This relationship can be 222 
potentially used as a proxy to predict the erosion time, depending on the pH of the media.  223 
Figure 4 224 
Figure 4 (A) shows the two products, Somac Control® and Pantaloc Control®, producing 225 
identical EDDDI BARDS spectra. Both samples are the same formulation and contain the same 226 
excipients. Whereas GSK is the marketing authorisation holder in Ireland for the two products, 227 
the listed manufacturer of both is Takeda GmbH. An experiment where one or two tablets, of the 228 
same brand, were analysed simultaneously in 0.01 M aq. NaOH also yielded similar EDDDI 229 
profiles on a per tablet basis, as shown in Figures 4 (B) and (C).  230 
The lag time of the black profile for the single tablet analysis of Pantoloc Control® can be seen 231 
in Figure 4 (B) and is approximately the same as that of the two tablet analysis (blue profile). 232 
This result mirrors a previous study which shows the lag time is independent of the number of 233 
microspheres dissolved in basic solution which have the same coating
14
 The fmin is lower in the 234 
two tablet analysis due to the higher mass of API and excipients present in the dissolution media. 235 
However, the disintegration rate of both experiments appears the same as indicated by the 236 
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downward slope (~600 s) of the frequency spectra. No return to steady-state is observed for the 237 
two tablet experiment as the solution becomes saturated, resulting in a suspension of 238 
disintegrated tablet contents. At the endpoint of the single-tablet analysis, there was complete 239 
dissolution of the tablet, affording a clear, colourless solution.  240 
The data in Figure 4(C) for Somac Control® 20 mg tablets are also dose-related. Simultaneous 241 
disintegration of two tablets occurs at a similar rate to that of a single tablet. The fmin value is 242 
reached at the same time point (1200 s) irrespective of the number of tablets. However, the fmin 243 
value is sustained for longer with two tablets due to more disintegration and deaggregation 244 
taking place in solution. The lag time does not differ and is 600 s for both analyses.  245 
 246 
Figure 5 247 
 248 
Pantoprazole Bluefish 20 mg and 40 mg tablet formulations were also comparatively analysed to 249 
determine their respective EDDDI profiles by BARDS, as shown in Figure 5(A). Tablets were 250 
added after 30 s of initiating the acquisition of acoustic data. The lag time is similar for both the 251 
20 mg and 40 mg tablets indicating the same enteric coating thickness has been applied to both 252 
formulations. Figure 5 (B) compares the simultaneous addition of one (black profile), two (red 253 
profile) or three (blue profile) 20 mg tablets to the dissolution vessel. The lag time of 270 s 254 
indicates that tablet erosion time remains the same irrespective of the tablet number. This 255 
observation is also true of enteric-coated microspheres and is only expected as long as the basic 256 
solution is not the limiting reagent of the enteric polymer carboxylic acid deprotination.
22
 There 257 
is no buffer capacity available to maintain this trend with an increasing number of tablets.  258 
Similar trends can be seen in Figure 5 (C) for tablets with a higher content of pantoprazole 259 
(Pantoprazole Bluefish 40 mg tablets). The rate of gas evolution, denoted by the negative slopes 260 
post-coating erosion, increases with a greater number of tablets due to a greater amount of 261 
disintegrant present in solution. This trend is evident for all products tested. However, the 262 
standard deviation also increases with a greater tablet number. Three times the amount of coating 263 
is eroding in a three tablet experiment. This also has the effect of increasing the oversaturation of 264 
gas in solution threefold. The surface area for gas nucleation also increases three-fold in the 265 
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presence of three tablets. This allows for the nucleation of the increased gas concentration on 266 
surfaces sooner than a single tablet experiment as amplified in Figure 5 (D). This theory is 267 
reinforced by the data for a two tablet experiment which forms part of a trend in shorter lag time 268 




Figure 6 271 
Fig 6 (A) shows the analysis of Protium® 20 mg and 40 mg tablets (black and red profiles, 272 
respectively). The lag time of both formulations are the same (220 s). A similar assumption can 273 
be made to that observed for Pantoprazole Bluefish (Figure 5) – the loading of the functional 274 
enteric polymer is the same for both dosage forms. The 20 mg Protium® tablet reaches a 275 
minimum acoustic frequency at 542 s, sooner than the 40 mg tablet which reaches the frequency 276 
minimum at 662 s; indicating a shorter disintegration time. This may be due to a reduced amount 277 
of disintegrant in the 40 mg tablet relative to the amount of API present. There is a prolonged 278 
frequency plateau at 8.3 kHz for the 40 mg tablet evident in Figure 7A and is likely a result of 279 
the gas evolution rate being in equilibrium with the rate of gas loss at the surface, indicating a 280 
longer disintegration period of 600 s. The return to baseline steady state is not achieved for either 281 
tablet due to insoluble excipients retaining gas and oversaturation of the solution, and is more 282 
evident for the 40 mg tablet.  283 
Fig 6 (B) compares the spectrum of the two Takeda-manufactured formulations analysed – 284 
Protium® 20 mg and Somac Control® 20 mg tablets. The lag times are approximately the same 285 
for both formulations, indicating little or no difference in polymer thickness. Their fmin also differ 286 
statistically. However, a difference of ~300 Hz relates to a very small difference in the gas 287 
volume produced by the two formulations. 288 
Figure 7 289 
Figure 7 (A) compares the BARDS spectra of all four 20 mg pantoprazole formulations under 290 
investigation. Pantoprazole Bluefish 20 mg (black profile) has the longest lag time, indicating the 291 
thickest polymer loading of all four formulations. In general, the lag time is the same for the 292 
other three formulations made by Takeda. The Bluefish tablet exhibits a slower disintegration 293 
rate but faster deaggregation as it returns to steady-state by 1250 s. The other three profiles for 294 
the Takeda-manufactured products (red, green and blue profiles) are very similar apart from the 295 
12 
 
frequency minima (fmin) value. The small differences in this value may be interpreted as inter-296 
batch variability. 297 
In comparison, the acoustic profiles of 40 mg pantoprazole-containing tablets from three 298 
different manufacturers are concurrently shown in Figure 7 (B). Their lag times, frequency 299 
minima and return to steady-state times are significantly different for all three formulations. 300 
Pantoprazole Mylan 40 mg tablets (black profile) have the thickest enteric coating as indicated 301 
by the longest lag time of 336 seconds. Protium® 40 mg (red profile) has the thinnest enteric 302 
coating corresponding with the shortest coating erosion time. Meanwhile, Pantoprazole Bluefish 303 
40 mg tablets (blue profile) exhibited the fastest rate of disintegration and also the lowest fmin of 304 
the 40 mg formulations studied.  305 
Note Pantaloc 20 mg (Figure 7 A, green profile) and Protium® 40 mg (Figure 7 B, red profile) 306 
both display a plateau at the fmin. The plateau represents an equilibrium between the rate of gas 307 
evolution in solution and the rate of loss at the surface according to Henry’s law and does not 308 
represent a frequency cut-off. 309 
BARDS can be used to track the individual processes associated with dissolution. BARDS 310 
spectra of enteric-coated tablet and microsphere drug formulations may be mapped using an 311 
Erosion, Disintegration, Deaggreation, Dissolution and coating Integrity (EDDDI) Plot. These 312 
plots can also be used to track the dissolution of tablet formulations in general. Figure 8 shows 313 
an EDDDI plot for the Bluefish 20 mg formulation. The red profile represents the UV-Vis 314 
analysis during the BARDS experiment. The UV-Vis profile measures the concentration of 315 
dissolved pantoprazole released from the tablet.  316 
Figure 8 317 
Sample addition occurs at 30 s post start of acoustic data acquisition. The initial decrease in the 318 
fundamental curve is due to entrained gas in the outer functional tablet polymer coating, 319 
followed by a subsequent return to a depressed frequency plateau (lagtime) during the erosion of 320 
the polymer. Note there is no pantoprazole released during the lag time (the first 300 s) as 321 
demonstrated by the UV-Vis data (red profile). Once the coating erodes, and the inner tablet core 322 
disintegrates, there is an immediate increase in the concentration of API in solution as indicated 323 
by the downward slope of the BARDS spectra. The fmin indicates an approximate end of 324 
13 
 
disintegration with ~ 50 % pantoprazole release correlated by the UV-Vis data. The end of the 325 
disintegration process is followed by continuing deaggregation of tablet components to release 326 
the remainder of the API. The frequency profile is gradually returning to steady-state in the 327 
BARDS spectrum during the deaggregation phase. Technically, the dissolution bracket seen in 328 
the EDDDI plot could also encompass the erosion process but has been used to cover the 329 
disintegration and deaggregation steps only to reflect API release. 330 
Figure 7 331 
In Figure 9 (A) the fmin of a Bluefish 20 mg tablet correlates with ~ 50 % pantoprazole release. 332 
This is also exhibited in Fig 10 (B-E). However, the Pantoprazole Mylan 40 mg tablet EDDDI 333 
plot (F) shows a pantoprazole percentage release of 100% at the fmin, indicating a more rapid 334 
release of the drug. This leads to the hypothesis that the API of this formulation may be located 335 
in the outer section of the tablet and less so in the tablet core, i.e. the concentration of 336 
pantoprazole is greater away from the core. For the remaining formulations (A – E), 337 
deaggregation of tablet particles allows remaining pantoprazole to be released over a more 338 
extended time period relative to Pantoprazole Mylan.  339 
 340 
5. Conclusion 341 
In summary, BARDS analysis of tablets is of significant benefit for determining coating 342 
integrity, tablet disintegration,break-up and indicating drug release. A single BARDS 343 
measurement can provide data relevant to dissolution processesall data requirements in a time-344 
efficient manner. BARDS measurements have been cross-validated usingby the conventional 345 
technique UV-Vis Spectrometry, allowing for the plotting of the method of trackingcorrelation 346 
of all dissolution processes intoknow as an EDDDI plot. BARDS data has shown a correlation 347 
between the lag time for the erosion of the tablet coatings with the basicity of the solvent used. 348 
Similarities between different brands but made by the same manufacturer, were apparent when 349 
tested using BARDS, e.g., Somac and Pantaloc which are both made by Takeda. The erosion 350 
time was found to be independent of the number of tablets dissolved for small tablets with a 351 
small surface area. However, a slight reduction in the erosion time was noted for multiple tablets 352 
with a relatively larger surface area due to conditions favouring greater gas nucleation (Figure 5 353 
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C). A different BARDS response is evident when a different formulation is used for 354 
pantoprazole, as shown in Figure 6 (B) even though the same manufacturer makes the tablets. 355 
Figure 7 shows that BARDS can qualitatively discriminate between pantoprazole formulations. 356 
The data represents a potential new regulatory method for the quality assurance of tablet 357 
formulations and product performance. It is therefore highly relevant to the topical discussion 358 
surrounding the quality of medicines and specifically what constitutes so-called ‘critical quality 359 
attributes’. 360 
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Figure 1: BARDS spectrum of the dissolution of Sodium Carbonate in 25 mL of Deionised water. 
Note the sample addition at the 30 s time point. 
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Figure 2 (A) Top view schematic diagram representing the contents of the dissolution chamber. 
(B) Top view photograph of the BARDS dissolution chamber. (C) External view of the 
instrument. (D) Tipper motor with a tablet sample of pantoprazole in a weighing boat ready for 
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Figure 3 (A) BARDS analysis of a Pantoprazole Mylan 40 mg tablet in various concentrations of 
aq. NaOH (B) Labelled and the adjusted x-axis of BARDS spectra Pantoprazole Mylan 40 mg 
tablet in various concentrations of aq. NaOH. The vertical lines indicate the end of the lag time 
for each concentration of NaOH. The black vertical line represents the time point of sample 
addition on the spectra (30 seconds)  
 
 
Figure 4 (A) BARDS analysis of Somac Control® (red) and Pantoloc Control® (black) 20 mg 
tablets in 0.01 M aq. NaOH, (B) BARDS multi-tablet analysis of Pantoloc Control® 20 mg 
tablets in 0.01 M aq. NaOH (one tablet – black; two tablets – blue) (C) BARDS multi-tablet 
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Figure 5 (A) BARDS EDDDI analysis of Pantoprazole Bluefish 20 mg (black) and 40 mg (red) 
tablet formulations in 0.06 M aq. NaOH (B) BARDS multi-tablet analysis of Pantoprazole 
Bluefish 20 mg tablets in 0.06 M aq. NaOH (C) BARDS multi-tablet analysis of Pantoprazole 
Bluefish 40 mg tablets in 0.06 M aq. NaOH (D) BARDS analysis of Pantoprazole Bluefish 40 mg 
tablets in 0.06 M aq. NaOH indicating the differences in the lag time for the multi-tablet 
analysis. 
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Figure 6 (A) BARDS EDDDI acoustic spectra of Protium® 20 mg (black) and 40 mg (red) 
gastro-resistant tablets in 25 mL of 0.06 aq M NaOH (B) BARDS acoustic spectra of Takeda-
manufactured products, Protium® 20 mg (red) and Somac Control® 20 mg (blue) tablet 
analysis in 0.06 M aq. NaOH. 
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Figure 7 BARDS spectra of a selection of (A) 20 mg and (B) 40 mg pantoprazole-containing 
enteric-coated tablet formulations in 25 mL of 0.06 M aq. NaOH. Note that the NaOH 
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Figure 8 EDDDI plot (black profile) of the dissolution of a Bluefish pantoprazole 20 mg tablet in 
25 mL of 0.06M aq. NaOH. Note: the red profile represents the UV-Vis analysis of the tablet, 
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Figure 9 EDDDI plots of Bluefish 20 mg (A), Protium® 20 mg (B), Protium® 40 mg (C), Somac 
Control® 20 mg (D), Pantaloc® 20 mg (E) and Mylan 20 mg (F) pantoprazole tablets . All 
samples were dissolved in 25 mL of 0.06M aq. NaOH.  All BARDS measurements are in 







Table 1: Pantoprazole-containing tablets under investigation. 




Somac® Control 20 mg Takeda  Takeda 402042 10/2020 
Pantoloc® 
Control 
20 mg Takeda GlaxoSmithKline 11518723 04/2021 
Pantoprazole 
Mylan 





Protium® 20 mg Takeda  Takeda 08291 01/2021 
Protium® 40 mg Takeda  Takeda 08518 01/2021 
Pantoprazole 
Bluefish 
20 mg Bluefish 
Pharmaceuticals 
Bluefish 418678 05/2021 
Pantoprazole 
Bluefish 
40 mg Bluefish 
Pharmaceuticals 
Bluefish 428400 08/2021 
 
Table(s)
Declaration of interests 
 
☐ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☒The authors declare the following financial interests/personal relationships which may be considered 






Drs. Seán McSweeney and Dara Fitzpatrick are directors of BARDS Acoustic Science Labs. 
*Conflict of Interest
Niamh O’Mahoney is a graduate student working under the supervision of Dara Fitzpatrick 
and carried out the majority of experiments using BARDS. Niamh also helped in drafting the 
manuscript and generation of Figures and Tables. 
 
John J Keating is a lecturer in Pharmacy and was involved in the conceptual discussions and 
experimental design of the research. He was involved in reviewing the manuscript and 
making significant improvements. 
 
Seán McSweeney is responsible for the development of the hardware and software of 
BARDS and it’s optimization. 
 
 Sam Hill  is a student at the David Jack Centre for R&D as a visiting undergraduate from 
Aston University, UK as part of the GSK Summer Work Experience. Sam worked on 
BARDS and EDDDI plots during his placement and applied the rationale to rapid 
disintegration tablets. 
 
Simon Lawrence worked on formulation studies at GSK which fed into this BARDS study. 
Simon supervised Sam on associated BARDS projects in GSK, Ware, UK. 
 
Dara Fitzpatrick is the originator of BARDS and supervises Niamh and was centrally 
involved in the development of the study and co-authoring the paper. 
 
*Credit Author Statement
